Such tests are increasingly moving beyond their origins in cutting-edge research and into the laboratory and diagnostic ...

US-based Eli Lilly's Kisunla drug and Japanese company Eisai's Leqembi (below), two breakthrough drugs for the diagnosis and ...

NfL was assessed using the ultrasensitive Simoa and microfluidic Ella platforms and with Lumipulse and Elecsys assays, ...

Regular physical activity slows the accumulation of p-tau181, a key Alzheimer’s biomarker, but its cognitive benefits ...

NfL was assessed using the ultrasensitive Simoa and microfluidic Ella platforms and with Lumipulse and Elecsys assays, ...

Simoa is a breakthrough in biomarker detection due to its extremely high sensitivity and specificity. This technology combines single-molecule immunocapture with fluorescence detection, capable of ...

School of Biomedical Engineering/Med-X Research Institute, Shanghai Jiao Tong University, Shanghai 210030, PR China ...

Ready to expand the possibilities of biomarker science? The Simoa® Accelerator Laboratory is a full-service center for biopharmaceutical research. The Accelerator Lab provides exploratory protein ...

Our group studies neuroinflammation in multiple neurological conditions (e.g. Multiple Sclerosis, Autoimmune Encephalitis and Brain Cancer), with a focus on the role of innate immunity and purinergic ...

Objectives: Post-stroke cognitive impairment (PSCI) is a common disease that may occur within 3 months after a stroke or even later. However, the mechanism of PSCI development is unclear. The present ...